390 related articles for article (PubMed ID: 34219224)
1. Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome.
Imdad A; Mackoff SP; Urciuoli DM; Syed T; Tanner-Smith EE; Huang D; Gomez-Duarte OG
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD012997. PubMed ID: 34219224
[TBL] [Abstract][Full Text] [Related]
2. Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
Cooper TE; Khalid R; Chan S; Craig JC; Hawley CM; Howell M; Johnson DW; Jaure A; Teixeira-Pinto A; Wong G
Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013631. PubMed ID: 37870148
[TBL] [Abstract][Full Text] [Related]
3. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
4. Interventions for preventing thrombosis in solid organ transplant recipients.
Surianarayanan V; Hoather TJ; Tingle SJ; Thompson ER; Hanley J; Wilson CH
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD011557. PubMed ID: 33720396
[TBL] [Abstract][Full Text] [Related]
5. Interventions for minimal change disease in adults with nephrotic syndrome.
Azukaitis K; Palmer SC; Strippoli GF; Hodson EM
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD001537. PubMed ID: 35230699
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
7. Interventions for dialysis patients with hepatitis C virus (HCV) infection.
Prabhu AR; Rao IR; Nagaraju SP; Rajwar E; Venkatesh BT; Nair N S; Pai G; Reddy NP; Suvarna D
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007003. PubMed ID: 37096802
[TBL] [Abstract][Full Text] [Related]
8. Metformin for preventing the progression of chronic kidney disease.
El-Damanawi R; Stanley IK; Staatz C; Pascoe EM; Craig JC; Johnson DW; Mallett AJ; Hawley CM; Milanzi E; Hiemstra TF; Viecelli AK
Cochrane Database Syst Rev; 2024 Jun; 6(6):CD013414. PubMed ID: 38837240
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952
[TBL] [Abstract][Full Text] [Related]
10. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
[TBL] [Abstract][Full Text] [Related]
11. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001892. PubMed ID: 30284724
[TBL] [Abstract][Full Text] [Related]
12. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD001892. PubMed ID: 33118160
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Tsujimoto H; Tsujimoto Y; Nakata Y; Fujii T; Takahashi S; Akazawa M; Kataoka Y
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD012467. PubMed ID: 32164041
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Tsujimoto H; Tsujimoto Y; Nakata Y; Fujii T; Takahashi S; Akazawa M; Kataoka Y
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD012467. PubMed ID: 33314078
[TBL] [Abstract][Full Text] [Related]
15. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.
Natale P; Palmer SC; Navaneethan SD; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2024 Apr; 4(4):CD006257. PubMed ID: 38682786
[TBL] [Abstract][Full Text] [Related]
17. Home versus in-centre haemodialysis for people with kidney failure.
Cheetham MS; Ethier I; Krishnasamy R; Cho Y; Palmer SC; Johnson DW; Craig JC; Stroumza P; Frantzen L; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2024 Apr; 4(4):CD009535. PubMed ID: 38588450
[TBL] [Abstract][Full Text] [Related]
18. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive agents for treating IgA nephropathy.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
[TBL] [Abstract][Full Text] [Related]
20. Interventions for preventing diarrhea-associated hemolytic uremic syndrome: systematic review.
Thomas DE; Elliott EJ
BMC Public Health; 2013 Sep; 13():799. PubMed ID: 24007265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]